Proteostasis Therapeutics, Inc. (PTI)
(Delayed Data from NSDQ)
$1.08 USD
+0.07 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.07 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.08 USD
+0.07 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.07 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Bet on Rising P/E With These 5 Top Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Proteostasis Therapeutics (PTI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Proteostasis (PTI) delivered earnings and revenue surprises of 19.05% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Bet on Rising Price-to-Earnings With 5 Top Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.
Vertex's Kalydeco Wins Approval in EU for CF in Children
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.
Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis
by Zacks Equity Research
Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis
5 Top Stocks With Rising P/E to Bet On
by Sanghamitra Saha
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Will Proteostasis Therapeutics (PTI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Proteostasis (PTI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
by Tirthankar Chakraborty
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
Coronavirus to Hit Apple Sales: Invest in Domestic Producers
by Tirthankar Chakraborty
With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.
Is Proteostasis Therapeutics (PTI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PTI) Outperforming Other Medical Stocks This Year?
Will Proteostasis Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Proteostasis Therapeutics
Options Traders Expect Huge Moves in Proteostasis (PTI) Stock
by Zacks Equity Research
Investors need to pay close attention to Proteostasis (PTI) stock based on the movements in the options market lately.
Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
Proteostasis Therapeutics (PTI) shares rose more than 7% in the last trading session, amid huge volumes.
Proteostasis Therapeutics, Inc. (PTI) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Proteostasis Therapeutics, Inc. (PTI).
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Are Options Traders Betting on a Big Move in Proteostasis Therapeutics (PTI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Proteostasis Therapeutics (PTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Enters Into Collaboration With Privately-Held Ribometrix
by Zacks Equity Research
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.